[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100489862":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":40,"centralContacts":48,"locations":54,"responsibleParty":552,"collaborators":554,"id":562,"slug":563,"hasResults":564,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":564,"sex":570,"minAge":571,"maxAge":572,"enrollmentInfo":573,"targetDuration":24,"studyType":576,"phases":577,"briefSummary":580,"conditions":581,"keywords":587,"overallStatus":89,"whyStopped":24,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":606},{"fullName":5,"class":6},"Princess Maxima Center for Pediatric Oncology","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Sub-study D","EXPERIMENTAL","Trametinib + dexamethasone + cyclophosphamide and cytarabine.\n\nEach cycle lasts 28 days.\n\nCycle 1: Trametinib is given orally continuously once a day in tablets or oral formulation depending on the age and weight of the patient. Dexamethasone is given intravenously (IV)\u002Forally on days 1 to 5. Cyclophosphamide is given IV on day 3. Cytarabine is given IV in two blocks of 4 days each one week apart from day 5.\n\nCycle 2 and subsequent cycles: Trametinib is given orally continuously once a day in tablets or oral formulation depending on the age and weight of the patient. Dexamethasone is given intravenously (IV)\u002Forally on days 1 to 5. Cyclophosphamide is given IV on day 1. Cytarabine is given IV in two blocks of 4 days each one week apart from day 3.\n\nPatients in dose level -1, receive only 1 block of cytarabine per cycle.\n\nAll patients receive age adapted intrathecal chemotherapy.",[13,14,15,16,17],"Drug: Trametinib","Drug: Dexamethasone","Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Intrathecal chemotherapy",[19,25,29,33,36],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Trametinib","Oral",[9],null,{"type":20,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Dexamethasone","Oral\u002F Intravenous",[9],{"type":20,"name":30,"description":31,"armGroupLabels":32,"otherNames":24},"Cyclophosphamide","Intravenous",[9],{"type":20,"name":34,"description":31,"armGroupLabels":35,"otherNames":24},"Cytarabine",[9],{"type":20,"name":37,"description":38,"armGroupLabels":39,"otherNames":24},"Intrathecal chemotherapy","IT: Methotrexate +\u002F- prednisone\u002Fhydrocortisone\u002Fcytarabine according to the degree of central nervous involvement",[9],[41,45],{"name":42,"affiliation":43,"role":44},"Paco Bautista, MD PhD","Princess Máxima Center","PRINCIPAL_INVESTIGATOR",{"name":46,"affiliation":43,"role":47},"Michel Zwaan, Prof. dr.","STUDY_CHAIR",[49],{"name":50,"role":51,"phone":52,"phoneExt":24,"email":53},"Anne Elsinghorst","CONTACT","+316 5000 6270","hem-ismart@prinsesmaximacentrum.nl",[55,72,87,103,118,133,146,159,172,185,198,213,226,239,252,265,280,295,308,323,336,349,362,375,389,404,419,429,442,455,470,485,500,513,526,539],{"facility":56,"status":57,"city":58,"state":24,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"St. Anna Kinderspital","NOT_YET_RECRUITING","Vienna","1090","Austria","AT",{"type":63,"coordinates":64},"Point",[65,66],16.37208,48.20849,{"lat":66,"lon":65},[69],{"name":70,"role":51,"phone":24,"phoneExt":24,"email":71},"Andishe Attarbaschi","andishe.attarbaschi@stanna.at",{"facility":73,"status":57,"city":74,"state":24,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Universitair Ziekenhuis Gent","Ghent","9000","Belgium","BE",{"type":63,"coordinates":79},[80,81],3.71667,51.05,{"lat":81,"lon":80},[84],{"name":85,"role":51,"phone":24,"phoneExt":24,"email":86},"Barbara De Moerloose","Barbara.DeMoerloose@uzgent.be",{"facility":88,"status":89,"city":90,"state":24,"zip":91,"country":92,"countryCode":93,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Rigshospitalet Copenhagen","RECRUITING","Copenhagen","DK-2100","Denmark","DK",{"type":63,"coordinates":95},[96,97],12.56553,55.67594,{"lat":97,"lon":96},[100],{"name":101,"role":51,"phone":24,"phoneExt":24,"email":102},"Rutta Tuckuviene","ruta.tuckuviene@regionh.dk",{"facility":104,"status":57,"city":105,"state":24,"zip":106,"country":107,"countryCode":108,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"Helsinki University Hospital, New Children's Hospital","Helsinki","FI00029","Finland","FI",{"type":63,"coordinates":110},[111,112],24.93545,60.16952,{"lat":112,"lon":111},[115],{"name":116,"role":51,"phone":24,"phoneExt":24,"email":117},"Antti Kyrönlahti","antti.kyronlahti@hus.fi",{"facility":119,"status":57,"city":120,"state":24,"zip":121,"country":122,"countryCode":123,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Hôpital des Enfants GH Pellegrin - CHU de Bordeaux","Bordeaux","33076","France","FR",{"type":63,"coordinates":125},[126,127],-0.58046,44.84124,{"lat":127,"lon":126},[130],{"name":131,"role":51,"phone":24,"phoneExt":24,"email":132},"Stephane Ducassou","stephane.ducassou@chu-bordeaux.fr",{"facility":134,"status":57,"city":135,"state":24,"zip":136,"country":122,"countryCode":123,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"CHRU Lille - Hôpital Jeanne de Flandre","Lille","59037",{"type":63,"coordinates":138},[139,140],3.05512,50.63391,{"lat":140,"lon":139},[143],{"name":144,"role":51,"phone":24,"phoneExt":24,"email":145},"Bigitte Nelken","brigitte.nelken@chu-lille.fr",{"facility":147,"status":57,"city":148,"state":24,"zip":149,"country":122,"countryCode":123,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"Centre Léon Bérard","Lyon","69 373",{"type":63,"coordinates":151},[152,153],4.84789,45.74906,{"lat":153,"lon":152},[156],{"name":157,"role":51,"phone":24,"phoneExt":24,"email":158},"Nathalie Garnier","nathalie.garnier@ihope.fr",{"facility":160,"status":57,"city":161,"state":24,"zip":162,"country":122,"countryCode":123,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"Hopital La Timone - Enfants","Marseille","13005",{"type":63,"coordinates":164},[165,166],5.38107,43.29695,{"lat":166,"lon":165},[169],{"name":170,"role":51,"phone":24,"phoneExt":24,"email":171},"Paul Saultier","paul.saultier@ap-hm.fr",{"facility":173,"status":57,"city":174,"state":24,"zip":175,"country":122,"countryCode":123,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"CHU Nantes Hôpital Mère-Enfant","Nantes","44093",{"type":63,"coordinates":177},[178,179],-1.55336,47.21725,{"lat":179,"lon":178},[182],{"name":183,"role":51,"phone":24,"phoneExt":24,"email":184},"Fanny Rialland","fanny.rialland@chu-nantes.fr",{"facility":186,"status":57,"city":187,"state":24,"zip":188,"country":122,"countryCode":123,"cosmosGeoPoint":189,"geoPoint":193,"contacts":194},"Hôpital Robert Debré","Paris","75019",{"type":63,"coordinates":190},[191,192],2.3488,48.85341,{"lat":192,"lon":191},[195],{"name":196,"role":51,"phone":24,"phoneExt":24,"email":197},"Marion Strullu","marion.strullu@aphp.fr",{"facility":199,"status":57,"city":200,"state":24,"zip":201,"country":202,"countryCode":203,"cosmosGeoPoint":204,"geoPoint":208,"contacts":209},"Universitätsklinikum Augsburg","Augsburg","86156","Germany","DE",{"type":63,"coordinates":205},[206,207],10.89851,48.37154,{"lat":207,"lon":206},[210],{"name":211,"role":51,"phone":24,"phoneExt":24,"email":212},"Michael Frühwald","Michael.Fruehwald@uk-augsburg.de",{"facility":214,"status":89,"city":215,"state":24,"zip":216,"country":202,"countryCode":203,"cosmosGeoPoint":217,"geoPoint":221,"contacts":222},"Charité Universitätsmedizin Berlin","Berlin","13353",{"type":63,"coordinates":218},[219,220],13.41053,52.52437,{"lat":220,"lon":219},[223],{"name":224,"role":51,"phone":24,"phoneExt":24,"email":225},"Arend von Stackelberg","arend.stackelberg@charite.de",{"facility":227,"status":57,"city":228,"state":24,"zip":229,"country":202,"countryCode":203,"cosmosGeoPoint":230,"geoPoint":234,"contacts":235},"Universitätsklinikum Essen","Essen","45147",{"type":63,"coordinates":231},[232,233],7.01228,51.45657,{"lat":233,"lon":232},[236],{"name":237,"role":51,"phone":24,"phoneExt":24,"email":238},"Dirk Reinhardt","dirk.reinhardt@uk-essen.de",{"facility":240,"status":57,"city":241,"state":24,"zip":242,"country":202,"countryCode":203,"cosmosGeoPoint":243,"geoPoint":247,"contacts":248},"Universitätsklinikum Frankfurt","Frankfurt","60590",{"type":63,"coordinates":244},[245,246],10.53333,49.68333,{"lat":246,"lon":245},[249],{"name":250,"role":51,"phone":24,"phoneExt":24,"email":251},"Jan-Hemming Klusmann","Jan-Henning.Klusmann@ukffm.de",{"facility":253,"status":57,"city":254,"state":24,"zip":255,"country":202,"countryCode":203,"cosmosGeoPoint":256,"geoPoint":260,"contacts":261},"Universitätsklinikum Münster","Münster","48149",{"type":63,"coordinates":257},[258,259],7.62571,51.96236,{"lat":259,"lon":258},[262],{"name":263,"role":51,"phone":24,"phoneExt":24,"email":264},"Birgit Burkhardt","birgit.burkhardt@ukmuenster.de",{"facility":266,"status":57,"city":267,"state":24,"zip":268,"country":269,"countryCode":270,"cosmosGeoPoint":271,"geoPoint":275,"contacts":276},"Our Lady's Hospital for Sick Children","Dublin","D12N512","Ireland","IE",{"type":63,"coordinates":272},[273,274],-6.24889,53.33306,{"lat":274,"lon":273},[277],{"name":278,"role":51,"phone":24,"phoneExt":24,"email":279},"Andrea Malone","andrea.malone@olchc.ie",{"facility":281,"status":57,"city":282,"state":24,"zip":283,"country":284,"countryCode":285,"cosmosGeoPoint":286,"geoPoint":290,"contacts":291},"Schneider's Children's Medical Center","Petah Tikva","4920235","Israel","IL",{"type":63,"coordinates":287},[288,289],34.88747,32.08707,{"lat":289,"lon":288},[292],{"name":293,"role":51,"phone":24,"phoneExt":24,"email":294},"Gil Gilad","gilgi@clalit.org.il",{"facility":296,"status":57,"city":297,"state":24,"zip":298,"country":284,"countryCode":285,"cosmosGeoPoint":299,"geoPoint":303,"contacts":304},"Sheba Medical Center Hospital","Ramat Gan","52621",{"type":63,"coordinates":300},[301,302],34.81065,32.08227,{"lat":302,"lon":301},[305],{"name":306,"role":51,"phone":24,"phoneExt":24,"email":307},"Bella Bielorai","bella.bielorai@sheba.health.gov.il",{"facility":309,"status":57,"city":310,"state":24,"zip":311,"country":312,"countryCode":313,"cosmosGeoPoint":314,"geoPoint":318,"contacts":319},"IRCCS Istituto Giannina Gaslini","Genova","16147","Italy","IT",{"type":63,"coordinates":315},[316,317],11.87211,45.21604,{"lat":317,"lon":316},[320],{"name":321,"role":51,"phone":24,"phoneExt":24,"email":322},"Concetta Micalizzi","concettamicalizzi@gaslini.org",{"facility":324,"status":57,"city":325,"state":24,"zip":326,"country":312,"countryCode":313,"cosmosGeoPoint":327,"geoPoint":331,"contacts":332},"Fondazione MBBM c\u002Fo Centro ML Verga","Monza","20900",{"type":63,"coordinates":328},[329,330],9.27246,45.58005,{"lat":330,"lon":329},[333],{"name":334,"role":51,"phone":24,"phoneExt":24,"email":335},"Carmelo Rizzari","carmelo.rizzari@gmail.com",{"facility":337,"status":57,"city":338,"state":24,"zip":339,"country":312,"countryCode":313,"cosmosGeoPoint":340,"geoPoint":344,"contacts":345},"Padova Azienda Ospedaliera","Padova","35128",{"type":63,"coordinates":341},[342,343],11.14261,44.38225,{"lat":343,"lon":342},[346],{"name":347,"role":51,"phone":24,"phoneExt":24,"email":348},"Marta Pillon","marta.pillon@unipd.it",{"facility":350,"status":57,"city":351,"state":24,"zip":352,"country":312,"countryCode":313,"cosmosGeoPoint":353,"geoPoint":357,"contacts":358},"Ospedale Pediatrico Bambino Gesù, IRCCS","Roma","0165",{"type":63,"coordinates":354},[355,356],11.10642,44.99364,{"lat":356,"lon":355},[359],{"name":360,"role":51,"phone":24,"phoneExt":24,"email":361},"Franco Locatelli","franco.locatelli@opbg.net",{"facility":363,"status":57,"city":364,"state":24,"zip":365,"country":312,"countryCode":313,"cosmosGeoPoint":366,"geoPoint":370,"contacts":371},"Ospedale Infantile Regina Margherita","Turin","10126",{"type":63,"coordinates":367},[368,369],7.68682,45.07049,{"lat":369,"lon":368},[372],{"name":373,"role":51,"phone":24,"phoneExt":24,"email":374},"Franca Fagioli","franca.fagioli@unito.it",{"facility":376,"status":89,"city":377,"state":377,"zip":378,"country":379,"countryCode":380,"cosmosGeoPoint":381,"geoPoint":385,"contacts":386},"Princess Máxima Center for Pediatric Oncology","Utrecht","3584CS","Netherlands","NL",{"type":63,"coordinates":382},[383,384],5.12222,52.09083,{"lat":384,"lon":383},[387],{"name":388,"role":51,"phone":24,"phoneExt":24,"email":53},"Anne A.L Elsinghorst",{"facility":390,"status":89,"city":391,"state":24,"zip":392,"country":393,"countryCode":394,"cosmosGeoPoint":395,"geoPoint":399,"contacts":400},"Oslo University Hospital","Oslo","0373","Norway","NO",{"type":63,"coordinates":396},[397,398],10.74609,59.91273,{"lat":398,"lon":397},[401],{"name":402,"role":51,"phone":24,"phoneExt":24,"email":403},"Jochen Büchner","jocbuc@ous-hf.no",{"facility":405,"status":57,"city":406,"state":24,"zip":407,"country":408,"countryCode":409,"cosmosGeoPoint":410,"geoPoint":414,"contacts":415},"Hospital Vall d'Hebron","Barcelona","08035","Spain","ES",{"type":63,"coordinates":411},[412,413],2.15899,41.38879,{"lat":413,"lon":412},[416],{"name":417,"role":51,"phone":24,"phoneExt":24,"email":418},"Pablo Velasco","pablo.velascopuyo@vallhebron.cat",{"facility":420,"status":57,"city":406,"state":24,"zip":421,"country":408,"countryCode":409,"cosmosGeoPoint":422,"geoPoint":424,"contacts":425},"Hospital Sant Joan de Déu de Barcelona","08950",{"type":63,"coordinates":423},[412,413],{"lat":413,"lon":412},[426],{"name":427,"role":51,"phone":24,"phoneExt":24,"email":428},"Jose Luis Dapena Diaz","joseluis.dapena@sjd.es",{"facility":430,"status":57,"city":431,"state":24,"zip":432,"country":408,"countryCode":409,"cosmosGeoPoint":433,"geoPoint":437,"contacts":438},"Hospital Infantil Universitario Niño Jesús","Madrid","28009",{"type":63,"coordinates":434},[435,436],-3.70256,40.4165,{"lat":436,"lon":435},[439],{"name":440,"role":51,"phone":24,"phoneExt":24,"email":441},"Alba Rubio San Simón","alba.rubio@salud.madrid.org",{"facility":443,"status":57,"city":444,"state":24,"zip":445,"country":408,"countryCode":409,"cosmosGeoPoint":446,"geoPoint":450,"contacts":451},"La Fe","Valencia","46026",{"type":63,"coordinates":447},[448,449],-0.37966,39.47391,{"lat":449,"lon":448},[452],{"name":453,"role":51,"phone":24,"phoneExt":24,"email":454},"Carol Fuentes","fuentes_car@gva.es",{"facility":456,"status":89,"city":457,"state":24,"zip":458,"country":459,"countryCode":460,"cosmosGeoPoint":461,"geoPoint":465,"contacts":466},"Karolinska university hospital","Stockholm","171 76","Sweden","SE",{"type":63,"coordinates":462},[463,464],18.06871,59.32938,{"lat":464,"lon":463},[467],{"name":468,"role":51,"phone":24,"phoneExt":24,"email":469},"Anna Nilsson","anna.nilsson.1@ki.se",{"facility":471,"status":57,"city":472,"state":24,"zip":473,"country":474,"countryCode":475,"cosmosGeoPoint":476,"geoPoint":480,"contacts":481},"University Children's Hospital Zürich","Zurich","CH-8032","Switzerland","CH",{"type":63,"coordinates":477},[478,479],8.55,47.36667,{"lat":479,"lon":478},[482],{"name":483,"role":51,"phone":24,"phoneExt":24,"email":484},"Nastassja Scheidegger","nastassja.scheidegger@kispi.uzh.ch",{"facility":486,"status":57,"city":487,"state":24,"zip":488,"country":489,"countryCode":490,"cosmosGeoPoint":491,"geoPoint":495,"contacts":496},"Bristol Royal Hospital for Children","Bristol","B52 8BJ","United Kingdom","UK",{"type":63,"coordinates":492},[493,494],-2.59665,51.45523,{"lat":494,"lon":493},[497],{"name":498,"role":51,"phone":24,"phoneExt":24,"email":499},"Kristina Marshall","kristina.marshall@uhbw.nhs.uk",{"facility":501,"status":57,"city":502,"state":24,"zip":503,"country":489,"countryCode":490,"cosmosGeoPoint":504,"geoPoint":508,"contacts":509},"Great Ormond Street Hospital for Children NHS Trust","London","WC1N 2BH",{"type":63,"coordinates":505},[506,507],-0.12574,51.50853,{"lat":507,"lon":506},[510],{"name":511,"role":51,"phone":24,"phoneExt":24,"email":512},"David O'Connor","david.oconnor@gosh.nhs.uk",{"facility":514,"status":57,"city":515,"state":24,"zip":516,"country":489,"countryCode":490,"cosmosGeoPoint":517,"geoPoint":521,"contacts":522},"Royal Manchester Children's Hospital","Manchester","M13 9WL",{"type":63,"coordinates":518},[519,520],-2.23743,53.48095,{"lat":520,"lon":519},[523],{"name":524,"role":51,"phone":24,"phoneExt":24,"email":525},"Denise Bonney","denise.bonney@mft.nhs.uk",{"facility":527,"status":57,"city":528,"state":24,"zip":529,"country":489,"countryCode":490,"cosmosGeoPoint":530,"geoPoint":534,"contacts":535},"Great North Children's Hospital","Newcastle","NE1 4LP",{"type":63,"coordinates":531},[532,533],-5.88979,54.21804,{"lat":533,"lon":532},[536],{"name":537,"role":51,"phone":24,"phoneExt":24,"email":538},"Frederik van Delft","Frederik.Van-Delft@newcastle.ac.uk",{"facility":540,"status":57,"city":541,"state":24,"zip":542,"country":489,"countryCode":490,"cosmosGeoPoint":543,"geoPoint":547,"contacts":548},"Royal Marsden NHS Trust","Sutton","SM2 5PT",{"type":63,"coordinates":544},[545,546],-0.2,51.35,{"lat":546,"lon":545},[549],{"name":550,"role":51,"phone":24,"phoneExt":24,"email":551},"Donna Lancaster","donna.lancaster@rmh.nhs.uk",{"type":553,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[555,557,560],{"name":556,"class":6},"Innovative Therapies For Children with Cancer Consortium",{"name":558,"class":559},"IBFM","INDUSTRY",{"name":561,"class":6},"Fight Kids Cancer","100489862","phase-1-hem-ismart-d-trametinib--dexamethasone--chemotherapy-in-children-with-relapsed-or-refractory-hematological-malignancies-100489862",false,"NCT05658640","HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies","International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Subprotocol D: Trametinib + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","HEM-iSMART D","Inclusion criteria\n\n1. Children between 1 year (≥ 12 months) and 18 years of age at the time of first diagnosis and less than 21 years at the time of inclusion. Patients under 6 years old must weigh at least 7 kg at the time of enrollment. Patients over 6 years old must weigh at least 10 kg at the time of enrollment.\n2. Performance status: Karnofsky performance status (for patients \\>12 years of age) or Lansky Play score (for patients\n\n   * 12 years of age) ≥ 50% (Appendix I).\n3. Written informed consent from parents\u002Flegal representative, patient, and age-appropriate assent before any study specific screening procedures are conducted, according to local, regional or national guidelines.\n4. Patients must have had molecular profiling and flow-cytometric analysis of their recurrent or refractory disease at a time-point before the first inclusion into this trial (see section 9.1 of this protocol for detailed description of the molecular diagnostics required). Drug response profiling and methylation is highly recommended but not mandatory.\n\n   Patients with molecular profiling at first diagnosis lacking molecular diagnostics at relapse or refractory disease may be allowed to be included after discussion with the sponsor.\n5. Patients whose tumor present RAS pathway activating mutations including but not limited to KRAS, NRAS, HRAS, FLT3, PTPN11, MAP2K1, MP2K1 hotspot mutations, cCBL; NF1 del, as detected by molecular profiling.\n6. Adequate organ function:\n\n   * RENAL AND HEPATIC FUNCTION (Assessed within 48 hours prior to C1D1) :\n\n     * Serum creatinine ≤ 1.5 x upper limit of normal (ULN) for age or calculated creatinine clearance as per the Schwartz formula or radioisotope glomerular filtration rate ≥ 60 mL\u002Fmin\u002F1.73 m2.\n     * Direct bilirubin ≤ 2 x ULN (≤ 3.0 × ULN for patients with Gilbert's syndrome).\n     * Alanine aminotransferase (ALT)\u002Fserum glutamic pyruvic transaminase (SGPT) ≤ 5 x ULN; aspartate aminotransferase (AST)\u002Fserum glutamic oxaloacetic transaminase\u002FSGOT ≤ 5 x ULN. Note: Patients with hepatic disfunction related to the underling disease can be eligible even if they do not fulfill the aforementioned values for hepatic transaminases. In these cases, patients need to be discussed with the sponsor to confirm the eligibility.\n   * CARDIAC FUNCTION:\n\n     * Shortening fraction (SF) \\>29% (\\>35% for children \\\u003C 3 years) and\u002For left ventricular ejection fraction (LVEF) ≥50% at baseline, as determined by echocardiography or MUGA.\n     * Absence of QTcF prolongation (QTc prolongation is defined as \\>450 msec on baseline ECG, using the Fridericia correction), or other clinically significant ventricular or atrial arrhythmia.\n\n   Exclusion Criteria\n7. Pregnancy or positive pregnancy test (urine or serum) in females of childbearing potential. Pregnancy test must be performed within 7 days prior to C1D1.\n8. Sexually active participants not willing to use highly effective contraceptive method (pearl index \\\u003C1) as defined in CTFG HMA 2020 (Appendix II) during trial participation and until 6 months after end of antileukemic therapy.\n9. Breast feeding.\n10. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome) in case of oral IMPs.\n11. Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to the study drugs, or drugs chemically related to study treatment or excipients that contraindicate their participation, including conventional chemotherapeutics (i.e. cytarabine and cyclophosphamide, intrathecal agents) and corticoids.\n12. Known active viral hepatitis or known human immunodeficiency virus (HIV) infection or any other uncontrolled infection.\n13. Severe concomitant disease that does not allow treatment according to the protocol at the investigator's discretion.\n14. Subjects unwilling or unable to comply with the study procedures.\n15. Previous treatment with trametinib.\n16. Current use of a prohibited medication or herbal preparation or requires any of these medications during the study.\n\n    See Section 7 and Appendix III for details. Drugs inducing QTc changes (prolongation of the QT interval or inducing Torsade de Points) are not permitted.\n17. Unresolved toxicity greater than NCI CTCAE v 5.0 ≥ grade 2 from previous anti-cancer therapy, including major surgery, except those that in the opinion of the investigator are not clinically relevant given the known safety\u002Ftoxicity profile of the study treatment (e.g., alopecia and\u002For peripheral neuropathy related to platinum or vinca alkaloid based chemotherapy) (Common Terminology Criteria for Adverse Events (CTCAE) (cancer.gov).\n18. Active acute graft versus host disease (GvHD) of any grade or chronic GvHD of grade 2 or higher. Patients receiving any agent to treat or prevent GvHD post bone marrow transplant are not eligible for this trial.\n19. Received immunosuppression post allogenic HSCT within one moth of study entry.\n20. History or current evidence of retina vein occlusion (RVO) or central serous retinopathy are excluded.\n21. Wash-out periods of prior medication:\n\n    1. CHEMOTHERAPY: At least 7 days must have elapsed since the completion of cytotoxic therapy, with the exception of hydroxyurea, 6-mercaptopurine, oral methotrexate and steroids which are permitted up until 48 hours prior to initiating protocol therapy. Patients may have received intrathecal therapy (IT) at any time prior to study entry.\n    2. RADIOTHERAPY: Radiotherapy (non-palliative) within 21 days prior to the first dose of drug. Palliative radiation in past 21 days is allowed.\n    3. HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): Autologous HSCT within 2 months prior to the first study drug dose; Allogeneic HSCT within 3 months prior to the first study drug dose.\n    4. IMMUNOTHERAPY: At least 42 days must have elapsed after the completion of any type of immunotherapy other than monoclonal antibodies (e.g. CAR-T therapy)\n    5. MONOCLONAL ANTIBODIES AND INVESTIGATIONAL DRUGS: At least 21 days or 5 times the half-life (whichever is shorter) from prior treatment with monoclonal antibodies or any investigational drug under investigation must have elapsed before the first study drug.\n    6. SURGERY: Major surgery within 21 days of the first dose. Gastrostomy, ventriculo-peritoneal shunt, endoscopic ventriculostomy, tumor biopsy and insertion of central venous access devices are not considered major surgery.","ALL","1 Year","21 Years",{"count":574,"type":575},26,"ESTIMATED","INTERVENTIONAL",[578,579],"PHASE1","PHASE2","HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed\u002Frefractory (R\u002FR) ALL and LBL. Sub-protocol D is a phase I\u002FII trial evaluating the safety and efficacy of trametinib in combination with dexamethasone, cyclophosphamide and cytarabine in children and AYA with R\u002FR ped ALL\u002FLBL whose tumor present with alterations in the RAS-RAF-MAPK pathway.",[582,583,584,585,586],"Acute Lymphoblastic Leukemia, in Relapse","Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma\u002FLeukaemia) Recurrent","Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma\u002FLeukaemia) Recurrent","Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma\u002FLeukaemia) Refractory","Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma\u002FLeukaemia) Refractory",[588,589,590,21,591,592,593,594,595,596],"Acute lymphoblastic leukemia","Lymphoblastic lymphoma","Biomarker driven clinical trial","Chemotherapy","Relapse","Refractory","Children","Adolescents","Young adults","2025-09-09",{"date":599,"type":600},"2025-09-16","ACTUAL",{"date":602,"type":600},"2023-11-14",{"date":604,"type":575},"2029-04-01",{"name":5,"class":6},36]